Drug Profile
Patritumab - Amgen/Daiichi Sankyo
Alternative Names: AMG-888; U3-1287Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Amgen; U3 Pharma
- Developer Daiichi Sankyo Company
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action ERBB-3 receptor modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Head and neck cancer
- No development reported Breast cancer; Solid tumours
Most Recent Events
- 28 Dec 2022 Discontinued - Phase-I for Breast cancer in Japan (IV)(Daiichi Sankyo pipeline, December 2022)
- 28 Nov 2020 No recent reports of development identified for phase-I development in Breast-cancer in Japan (IV)
- 07 Jan 2019 Daiichi Sankyo terminates a phase II trial in Head and neck cancer (Combination therapy, First-line therapy, Metastatic disease) in Hungary, Belgium, France, Poland, Romania, United Kingdom, Germany (IV) (NCT02633800)